[autismo-biologia] palmitoiletanolamide (Pea)

[daniela]

Il 2024-02-05 19:21 Colla, Carlo ha scritto:
> Buonasera,
> 
> Cosa ne dite dell’integratore palmitoiletanolamide (Pea) e sue
> applicazioni/effetti per l’autismo ? Qualcuno ne ha già sentito
> parlare ?
> 
> Grazie mille
> 
> Carlo
> 
> 
Nel 2021 è uscita una review che si puo’ leggere integralmente in rete

Colizzi M, Bortoletto R, Costa R, Zoccante L. Palmitoylethanolamide and 
Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic 
Review of Human and Animal Evidence. Nutrients. 2021 Apr 18;13(4):1346. 
doi: 10.3390/nu13041346. PMID: 33919499; PMCID: PMC8073263.

https://www.mdpi.com/2072-6643/13/4/1346


Copio dall’articolo quanto segue
“ Palmitoylethanolamide (PEA) is a naturally occurring saturated 
N-acylethanolamine that has proven to be effective in controlling 
inflammation, depression, epilepsy, and pain, possibly through a 
neuroprotective role against glutamate toxicity. ….

 Limited research suggests that PEA supplementation reduces overall 
autism severity by improving language and social and nonsocial 
behaviors. Potential neurobiological underpinnings include modulation of 
immune response, neuroinflammation, neurotrophy, apoptosis, 
neurogenesis, neuroplasticity, neurodegeneration, mitochondrial 
function, and microbiota activity, possibly through peroxisome 
proliferator-activated receptor-α (PPAR-α) activation”


Ci sono buone premesse per fare delle sperimentazioni nel campo dello 
spettro autistico.

Una sperimentazione sta partendo all’Università di Udine a cura di Marco 
Colizzi

"The Supplementation Therapy in Autism and Response to Treatment Study 
(START)
December 15, 2023 updated by: University of Udine
The Supplementation Therapy in Autism and Response to Treatment (START) 
Study"

https://ichgcp.net/clinical-trials-registry/NCT06187090

Copio dal sito quanto segue
"Through this study, we wish to evaluate: the ability of PEA to 
alleviate symptoms of psychic distress (i.e., anxiety and/or depression) 
in Level 1 autistic adults; the safety and tolerability of sustained 
intake of PEA in Level 1 autistic adults; and the biological basis of 
PEA functioning…...

Volunteers who express an interest in the study and are identified as 
having Level 1 autistic individuals with comorbid anxiety and/or 
depressive symptoms by their clinical teams will be approached by study 
researchers and given a patient information sheet. Those who agree to 
take part in the study will be invited for a screening visit…….


As the present study was designed to assess the effect of PEA on 
mentally fragile conditions with interference in the global functioning 
of autistic individuals, we will focus on subjects with severity level 
1, more affected by depressive and anxious symptoms than autistic 
subjects with higher levels of impairment, requiring a prioritisation of 
these manifestations compared to core symptoms”

La sperimentazione è ancora in fase di reclutamento per cui chi ha le 
caratteristiche richieste dalla sperimentazione (adulti con autismo di 
livello 1  con associati sintomi di ansia e/o depressione ) potrebbe 
candidarsi a partecipare rivolgendosi a  marco.colizzi a uniud.it o 
bortoletto.riccardo a spes.uniud.it

     Daniela Mariani Cerati